Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters

Reuters | Dec. 15, 2025, 11 a.m. | Original
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research Reuters
NYSE Says seven of 2025’s Top 10 IPOs Debuted on Its Exchange - TradingView — Track All Markets NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:01 AM - TradingView — Track All Markets